Clinical Trial Update: Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vosaroxin with azacitidine for newly diagnosed acute myeloid leukemia or Myelodysplastic Syndrome with excess blasts-2 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts-2

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Vosaroxin (vosaroxin)

Snippet

Sponsor: University of Ulm | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) | Phase 2 | Status: COMPLETED